Pakistan journal of pharmaceutical sciences · 2026
Efficacy and influencing factors of piperacillin sodium tazobactam sodium combined with moxifloxacin in the treatment of severe pneumonia in the elderly.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Huacheng, Zhong Weixi, Sun Jian
Аннотация
BACKGROUND: Elderly patients with severe pneumonia face elevated mortality from complex, often resistant, polymicrobial infections.
OBJECTIVE: This investigation aimed at assessing the efficacy and determinants of PTZ plus moxifloxacin for severe elderly pneumonia.
METHODS: Retrospectively, this study evaluated 120 elderly severe pneumonia patients (2021-2024), grouped by treatment: Control (n=60): IV piperacillin-tazobactam (PTZ), 4.5g q6h; observation (n=60): PTZ + daily moxifloxacin 400mg. Primary outcomes pathogen resistance/clearance; secondary: 30-day mortality, readmission, CURB-65, ventilation duration, serum biomarkers. Logistic regression identified mortality factors; adverse events were recorded.
RESULTS: Baseline characteristics were comparable between groups (P>0.05). The observation group demonstrated superior primary outcomes (P<0.001) and pathogen clearance (P=0.013). No significant intergroup differences were found in secondary outcomes, including mortality, readmission, PLT and adverse events. Post-treatment CURB-65≥3, PCT and CRP significantly correlated with 30-day mortality (all P<0.001).
CONCLUSION: The moxifloxacin-PTZ regimen enhanced microbial clearance without affecting survival, readmission, or adverse event rates, supporting its targeted clinical use.
OBJECTIVE: This investigation aimed at assessing the efficacy and determinants of PTZ plus moxifloxacin for severe elderly pneumonia.
METHODS: Retrospectively, this study evaluated 120 elderly severe pneumonia patients (2021-2024), grouped by treatment: Control (n=60): IV piperacillin-tazobactam (PTZ), 4.5g q6h; observation (n=60): PTZ + daily moxifloxacin 400mg. Primary outcomes pathogen resistance/clearance; secondary: 30-day mortality, readmission, CURB-65, ventilation duration, serum biomarkers. Logistic regression identified mortality factors; adverse events were recorded.
RESULTS: Baseline characteristics were comparable between groups (P>0.05). The observation group demonstrated superior primary outcomes (P<0.001) and pathogen clearance (P=0.013). No significant intergroup differences were found in secondary outcomes, including mortality, readmission, PLT and adverse events. Post-treatment CURB-65≥3, PCT and CRP significantly correlated with 30-day mortality (all P<0.001).
CONCLUSION: The moxifloxacin-PTZ regimen enhanced microbial clearance without affecting survival, readmission, or adverse event rates, supporting its targeted clinical use.